Jose Puente Moreno, MD
Family Medicine · Tulare, CANPI 1992490544
Payments from drug & device makers
Across 73 payments — averaging $31.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$647
- Novo Nordisk$314
- AstraZeneca$293
- Amgen$235
- Lilly USA, LLC$149
- Optinose US, Inc.$125
- plus $523 from 14 others
What the payments were for
- Food & beverage$2,286100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $647 |
| Novo Nordisk | 11 | $314 |
| AstraZeneca | 6 | $293 |
| Amgen(2 entities) | 10 | $235 |
| Lilly USA, LLC | 4 | $149 |
| Optinose US, Inc. | 1 | $125 |
| Viiv Healthcare Company | 1 | $121 |
| Boehringer Ingelheim | 1 | $89 |
| Bayer | 2 | $55 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| Exact Sciences | 2 | $33 |
| Mannkind Corporation | 1 | $27 |
| Hologic Sales And Service, LLC | 1 | $27 |
| CSL Behring | 1 | $26 |
| Verrica Pharmaceuticals Inc. | 1 | $23 |
| Pfizer | 1 | $22 |
| Shield Therapeutics Inc | 1 | $18 |
| Merck | 1 | $15 |
| Neurelis, Inc. | 1 | $14 |
| Organon | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,286 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 43 | $41,100 |
| FarxigaDapagliflozin Propanediol | 36 | $38,787 |
| JardianceEmpagliflozin | 35 | $37,315 |
| RybelsusSemaglutide | 25 | $30,247 |
| TrulicityDulaglutide | 32 | $30,191 |
| KerendiaFinerenone | 16 | $19,620 |
| MounjaroTirzepatide | 19 | $17,898 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 16 | $17,242 |
| GemtesaVibegron | 20 | $13,825 |
| LinzessLinaclotide | 21 | $11,514 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $6,949 |
| Esomeprazole Magnesium | 40 | $3,625 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,414 |
| Celecoxib | 55 | $1,685 |
| Duloxetine Hcl | 25 | $757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $314 | $71,34668 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $89 | $54,55851 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $149 | $48,08951 claims |
| AstraZenecaFarxiga | $293 | $38,78736 claims |
| BayerKerendia | $55 | $19,62016 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $47 | $13,82520 claims |
| AbbVieLinzess | $647 | $11,51421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Tulare
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.